WHO ICTRP trial
Study in which melanoma patients are treated with pembrolizumab combined with…
EUCTR2015-003120-31-NL · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2015-003120-31-NL |
|---|---|
| Public title | Study in which melanoma patients are treated with pembrolizumab combined with dabrafenib and trametinib. |
| Scientific title | Phase 2 Study Comparing Pembrolizumab with Intermittent/Short-term Dual MAPK Pathway Inhibition Plus Pembrolizumab in patients harboring the BRAFV600 mutation (IMPemBra) - IMPemBra |
| Primary sponsor | Antoni van leeuwenhoek ziekenhuis |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Netherlands |
| Conditions | Irresectable stage III and stage IV melanoma MedDRA version: 20.0 Level: LLT Classification code 10027481 Term: Metastatic melanoma System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] |
| Interventions | Product Name: Pembrolizumab Product Code: MK3475 Pharmaceutical Form: Solution for infusion INN or Proposed INN: PEMBROLIZUMAB CAS Number: 1374853-91-4 Current Sponsor code: MK-3475 Other descriptive name: Anti-PD-1 monoclonal antibody… |
| Registration date | Sep 28, 2015 |
| Target size | 32 |
| Secondary IDs | N15IMP;NCT02625337 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: